Maxcyte (MXCT) Common Equity (2019 - 2026)

Maxcyte (MXCT) has 8 years of Common Equity data on file, last reported at $167.9 million in Q1 2026.

• Quarterly Common Equity fell 15.81% year-over-year to $167.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $167.9 million (down 15.81% YoY) and the FY2025 annual result came in at $171.5 million, down 16.85% from the prior year.
• Common Equity slipped to $167.9 million in Q1 2026 per MXCT's latest filing, from $171.5 million in the prior quarter.
• Across five years, Common Equity topped out at $262.2 million in Q1 2022 and bottomed at $167.9 million in Q1 2026.
• The 5-year median for Common Equity is $226.4 million (2024), against an average of $221.1 million.
• The widest annual swing landed in 2022, when Common Equity surged 226.34%; it then retreated 16.85% in 2025.
• Tracing MXCT's Common Equity over 5 years: stood at $254.0 million in 2022, then decreased by 8.58% to $232.2 million in 2023, then dropped by 11.16% to $206.3 million in 2024, then dropped by 16.85% to $171.5 million in 2025, then declined by 2.1% to $167.9 million in 2026.
• Per Business Quant, the three latest MXCT Common Equity figures stand at $167.9 million (Q1 2026), $171.5 million (Q4 2025), and $180.3 million (Q3 2025).

Peer Comparison